DCC-2618-99-001: Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies
This Expanded Access Program is intended to provide access to ripretinib (DCC-2618) treatment for patients with locally advanced unresectable or metastatic GIST. Additionally, it aims to further characterize the safety and effectiveness of ripretinib.
Gastrointestinal Stromal Tumors (GIST)
1. Male or female patients, ≥ 18 years of age at the time of informed consent
2. Histologic diagnosis of GIST
3. Patients must have received prior treatment with at least 2 of the FDA approved drugs for GIST: imatinib, sunitinib, and regorafenib.
Additional criteria may apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
This is an expanded access study and, thus, no sample size and no power computation will be performed. Patient will receive ripretinib until it becomes commercially available or the Sponsor chooses to discontinue the program.
Knight Clinical Trials Information Line